Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.49 |
| ▸ | MME | P08473 | 4/20 | 0.49 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.47 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198783 | 0.91 | GPR132 (0.52) | ECE1GPR132MMECMKLR2CMKLR1 | |
| SCHEMBL29743017 | 0.90 | ECE1 (0.51) | ECE1GPR132MME | |
| SCHEMBL30724704 | 0.86 | GPR132 (0.48) | ECE1GPR132MMECMKLR2CMKLR1 | |
| SCHEMBL29603169 | 0.85 | NAALAD2 (0.51) | GPR132MMECMKLR2CMKLR1FOLH1 | |
| SCHEMBL29937707 | 0.85 | MME (0.66) | MMEMMP2FNTAFNTBPGGT1B | |
| SCHEMBL14958103 | 0.85 | MME (0.66) | MMEMMP2FNTAFNTBPGGT1B | |
| SCHEMBL16421158 | 0.85 | MME (0.66) | MMEMMP2FNTAFNTBPGGT1B | |
| SCHEMBL14787211 | 0.85 | MME (0.66) | MMEMMP2FNTAFNTBPGGT1B | |
| SCHEMBL4436681 | 0.85 | GPR132 (0.51) | GPR132MMECMKLR2CMKLR1FOLH1 | |
| SCHEMBL31754274 | 0.84 | FOLH1 (0.48) | GPR132MMECMKLR2CMKLR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339568-A1 | PRECURSOR AND RADIOTRACER FOR NEUROENDOCRINE THERANOSTICS | ITM Oncologics GmbH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4333909-A1 | PRECURSOR AND RADIOTRACER FOR NEUROENDOCRINE THERANOSTICS | Positron Precision GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117545513-A | Precursors and radiotracers for diagnosis of neuroendocrine therapy | 正电子精密股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022233768-A1 | PRECURSOR AND RADIOTRACER FOR NEUROENDOCRINE THERANOSTICS | Positron Precision GmbH (DE) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339568-A1 | PRECURSOR AND RADIOTRACER FOR NEUROENDOCRINE THERANOSTICS | SSTR5, SSTR2, SLC6A2 | ECE1 3069/4885GPR132 764/4885MME 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.